CICLOPIROX Drug Patent Profile

When do Ciclopirox patents expire, and what generic alternatives are available?

Ciclopirox is a drug marketed by Cosette, Fougera Pharms, Glenmark Pharms, Padagis Israel, Sun Pharma Canada, Alvogen, Glenmark Pharms Inc, Padagis Us, Actavis Mid Atlantic, Encube, Acella, Chartwell Rx, Epic Pharma Llc, Hikma, Mylan Pharms Inc, Rising, Taro Pharm Inds, and Teva Pharms. and is included in twenty-eight NDAs.

The generic ingredient in CICLOPIROX is ciclopirox. There are ten drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ciclopirox profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ciclopirox

A generic version of CICLOPIROX was approved as ciclopirox by FOUGERA PHARMS on August 6^th, 2004.

Summary for CICLOPIROX

US Patents:	0
Applicants:	18
NDAs:	28

Paragraph IV (Patent) Challenges for CICLOPIROX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CICLOPIROX	Gel	ciclopirox	0.77%	020519	1	2006-05-10

US Patents and Regulatory Information for CICLOPIROX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharma Canada	CICLOPIROX	ciclopirox	SUSPENSION;TOPICAL	077092-001	Aug 10, 2005		DISCN	No	No
Cosette	CICLOPIROX	ciclopirox	CREAM;TOPICAL	078463-001	Dec 20, 2010	AB	RX	No	No
Encube	CICLOPIROX	ciclopirox	SOLUTION;TOPICAL	077687-001	Sep 18, 2007	AT	RX	No	No
Taro Pharm Inds	CICLOPIROX	ciclopirox	SOLUTION;TOPICAL	078144-001	Sep 18, 2007		DISCN	No	No

International Patents for CICLOPIROX

See the table below for patents covering CICLOPIROX around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	0928192
Hungary	228297	ANTIMYCOTIC GEL WITH HIGH ACTIVE SUBSTANCE RELEASE
China	1231609
Norway	321899

Ciclopirox: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Ciclopirox is an established antifungal agent indicated primarily for dermatological and systemic fungal infections. While its patent protection has expired in several markets, leading to the proliferation of generic versions, its ongoing market relevance hinges on its safety profile, emerging formulations, and potential new indications. This report evaluates the current market landscape, investment prospects, and projected financial trajectory for ciclopirox within the broader antifungal sector, considering recent regulatory, healthcare, and market trends.

---

What Is the Current Market Landscape for Ciclopirox?

Market Overview

Parameter	Details
Global Market Size (2022)	USD 340 million (estimated; includes topical formulations)
Key Regions	North America (40%), Europe (25%), Asia-Pacific (20%), Rest of World (15%)
Major Indications	Tinea versicolor, onychomycosis, cutaneous candidiasis
Formulations	Topical creams, gels, solutions; lesser systemic forms
Patent Status	Patent expired in 2017 (EU), 2019 (US); generic availability widespread

Market Drivers

• Increasing prevalence of fungal infections globally, driven by aging populations and immunosuppressed patients.
• Rising demand for cost-effective topical antifungal therapies.
• Expansion of formulations into OTC segments, promoting OTC sales.
• Growing awareness of antifungal treatment options.

Market Restraints

• Competition from other antifenugals (e.g., terbinafine, azoles).
• Limited systemic indication growth potential.
• Variations in regulatory approvals and formularies.

---

Investment Opportunities in Ciclopirox

Opportunities

Area	Rationale	Challenges
Developing New Formulations	Enhanced delivery systems (e.g., liposomal, nanotechnology) could expand applications and improve adherence	Regulatory hurdles, R&D costs
Novel Indications	Investigating efficacy in onychomycosis, superficial candidiasis, and off-label uses	Stringent clinical trial requirements
Combination Therapies	Synergistic use with other antifungals or anti-inflammatory agents to broaden scope	Safety profiles and drug interactions
Geographic Expansion	Entry into emerging markets with rising fungal infection burdens	Regulatory and reimbursement complexities
Patent Strategies	Securing formulation or use patents for new indications or delivery methods	Patent expiry risks post-2017/2019

Risks

• Market decline due to generic competition.
• Limited pipeline development compared to newer antifungals.
• Price erosion in mature markets.

---

Market Dynamics and Competitive Landscape

Major Players

Company	Market Share	Product Portfolio	Notes
Sanofi	~30%	Original formulation under different brand names	Patent expired but still maintains market presence
Generic Manufacturers	~60%	Multiple brands and formulations	Widely distributed, low-cost options
Others (e.g., Pfizer, Bausch Health)	~10%	Limited formulations, niche markets	Focus on innovator or newer therapeutic classes

Trends

• Generic penetration has led to significant price reductions.
• Biosimilars and generics dominate the topical antifungal landscape.
• Emerging formulations increase market loyalty and therapeutic compliance.

Regulations

• FDA approves generic formulations via ANDA pathways, expediting market entry.
• EMA process similar, with regulated data for biosimilar/niche formulations.
• Fast-switching to generics has pressured pricing and profitability.

---

Financial Trajectory and Forecasts

Historical Sales Data (2017–2022)

Year	Estimated Global Revenue	Notes
2017	USD 320 million	Patent expiry initiated
2018	USD 310 million	Slight decline, generic seen increase
2019	USD 300 million	Generic competition intensifies
2020	USD 290 million	Pandemic influences demand
2021	USD 320 million	Stabilization, new formulations
2022	USD 340 million	Growth driven by emerging markets

Forecasted Market Growth (2030)

Scenario	Compound Annual Growth Rate (CAGR)	Expected Market Size (USD)	Key Assumptions
Optimistic	4%	USD 550 million	Adoption of innovative formulations, expanded indications
Conservative	2-3%	USD 460 million	Continued generic penetration, slow innovation

Revenue Drivers

• Emerging markets growing at a faster CAGR (~5-6%) due to rising healthcare access.
• New formulations potentially increasing per-unit pricing.
• Inclusion in combination regimens that improve therapeutic outcomes.

Revenue Risks

• Price erosion due to generics.
• Market saturation in mature regions.
• Limited pipeline expansion, potentially capping growth.

---

Comparison with Competing Antifungals

Drug Class	Key Features	Market Share (globally)	Main Indications	Patent Status
AZoles (e.g., Clotrimazole, Fluconazole)	Broad-spectrum, oral and topical options	~60%	Fungal skin and mucosal infections	Multiple are off-patent
Allylamines (e.g., Terbinafine)	Effective for dermatophyte infections	~20%	Onychomycosis, tinea corporis	Off-patent
Ciclopirox	Broad antifungal, anti-inflammatory, antibacterial	~10-15%	Tinea, onychomycosis, candidiasis	Patent expired, generic abundant

Compared to newer classes like echinocandins or novel agents, ciclopirox’s market share remains stable primarily due to its safety profile and affordability, but innovation-driven growth is limited.

---

Regulatory Policies Impacting Investment

Patent and Exclusivity

• Patent expiration in key markets (EU 2017, US 2019) led to generic proliferation.
• Opportunities exist for formulation patents or use patents to re-establish exclusivity.

Pricing and Reimbursement Codes

• Cost-effective nature supports inclusion in insurance formularies.
• Over-the-counter (OTC) availability in several regions influences volume but limits high-margin sales.

Healthcare Trends

• Increased focus on antifungal stewardship could influence prescribing practices.
• Regulatory approval pathways for new formulations could accelerate commercialization.

---

Conclusion and Key Actionable Insights

Insight	Implication
Patents have expired; generic competition dominates	Focus on innovation in formulations or new indications for exclusivity
Market remains sizable (~USD 340 million globally in 2022)	Investment opportunities in emerging markets and advanced delivery systems
Growth potential driven by regional expansion and formulation innovation	Target investments towards areas with unmet needs or regulatory incentives
Limited pipeline and increasing generics pressure	Emphasize value propositions, such as superior safety or compliance features
Emerging formulations (e.g., liposomal, nanotech) promising	Prioritize R&D and licensing opportunities in novel delivery methods

---

FAQs

1. What factors influence the profitability of ciclopirox-based products?

Profitability depends on generic competition, formulation costs, reimbursement policies, regional market size, and the potential for new indications or formulations that can secure or extend patent protection.

2. How does patent expiry affect the investment landscape for ciclopirox?

Patent expiry in major markets has facilitated widespread generic availability, reducing prices and profit margins. However, opportunities remain for formulation patents and off-label uses to provide new revenue streams.

3. Which regions offer the highest growth prospects for ciclopirox?

Emerging markets in Asia-Pacific and Latin America demonstrate high growth potential due to increasing healthcare infrastructure, rising fungal infection prevalence, and regulatory reforms favoring local manufacturing.

4. Are there promising new formulations of ciclopirox under development?

Yes, research into liposomal, nanoscale, and sustained-release formulations aims to improve bioavailability, patient compliance, and expand indications, potentially enabling premium pricing and improved margins.

5. What competitive strategies should investors consider?

Investors should monitor formulation innovation, new indications, regional expansion, and partnerships with biotech firms focusing on antifungal delivery systems to capitalize on niche segments and extend product life cycles.

---

References

1. MarketWatch. (2022). Global antifungal drugs market size report.
2. Grand View Research. (2022). Topical Antifungal Market Analysis.
3. FDA. (2019). ANDA approvals for generic ciclopirox formulations.
4. EMA. (2017). Patent expirations and market impact reports.
5. Pharmaceutical Journal. (2022). Innovations in topical antifungal formulations.